Search | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects with Advanced Hematologic Malignancies with an IDH1 Mutation

    ... after the start of AG-120). Subjects who received an investigational agent <14 days prior to their first day of study drug ... with tumor fever may be enrolled). Subjects with New York Heart Association (NYHA) Class III or IV congestive heart failure or ...

    Clinical Trial last updated 02/22/2017 - 11:21am.

  2. Like AAMDSIF, HHS now provides more info on clinical trials

    ... summary results information to ClinicalTrials.gov. The new rule expands the legal requirements for submitting registration and results ... trials in which they may be able to participate and access investigational therapies. More information about the scientific results of ...

    Article last updated 11/22/2016 - 2:05pm.

  3. Unraveling Myelodysplastic Syndromes: Current Knowledge and Future Directions

    ... of these diseases challenging. In fact, there have been no new drug approvals for MDS in the USA in the last 9 years, and few currently available investigational drugs are likely to be approved in the near future. Novel ...

    Research Article last updated 04/29/2016 - 11:23am.

  4. Safety Study of Cord Blood Units for Stem Cell Transplants

    ... the FDA published a guidance in August 2011 titled Investigational New Drug Applications (INDs) for Minimally Manipulated, Unrelated Allogeneic ...

    Clinical Trial last updated 04/27/2016 - 2:25pm.

  5. Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

    ... participant without clinically significant encephalopathy/new focal deficits Infectious diseases: no clinical evidence of ... 4 weeks of enrollment Currently enrolled in another investigational therapy protocol Participants with presence of ...

    Clinical Trial last updated 07/14/2016 - 4:08pm.

  6. Transplants With Unlicensed Preserved Cord Blood

    ... the FDA published a guidance in August 2011 entitled Investigational New Drug Applications (INDs) for Minimally Manipulated, Unrelated ...

    Clinical Trial last updated 04/27/2016 - 3:20pm.

  7. SL-401 in Advanced, High Risk Myeloproliferative Neoplasms (Systemic Mastocytosis, Advanced Symptomatic Hypereosinoophic Disorder, Myelofibrosis, Chronic Myelomonocytic Leukemia)

    ... study entry Patient has received treatment with another investigational agent within 14 days of study entry or concurrent treatment ... cardiovascular disease (e.g., uncontrolled or any New York Heart Association Class 3 or 4 congestive heart failure, uncontrolled ...

    Clinical Trial last updated 06/06/2016 - 2:11pm.

  8. A Trial to Evaluate Two Schedules of MS275 in Combination With 5AC in Elderly Patients With Acute Myeloid Leukemia (AML)

    ... This research is being done to help us learn how to best use new drugs which may be active against acute myeloid leukemia (AML). Two study ... at least three months. Patients must be informed of the investigational nature of the treatment, results that might be expected, and ...

    Clinical Trial last updated 06/03/2016 - 3:09pm.

  9. Phase I/II MEK162 Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Poor Prognosis, Not Suitable for or Unwilling to Receive Standard Therapy

    ... of the study drug. Patients should not have received an investigational agent for at least 2 weeks prior to the first study drug dose. ... atrophy). Patients who are planning on embarking on a new strenuous exercise regimen after first dose of study treatment. NB: ...

    Clinical Trial last updated 06/06/2016 - 10:59am.

  10. Midostaurin and Azacitidine in Treating Elderly Patients With Acute Myelogenous Leukemia

    ... Zarnestra, Revlimid, arsenic, SAHA inhibitors, or any investigational medication; a minimum of five days must have elapsed since the ... to starting study drug; Congestive heart failure (CHF) New York (NY) Heart Association class III or IV; Patients with an ejection ...

    Clinical Trial last updated 06/03/2016 - 2:24pm.